News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Canterbury Park Ups Paragon Pharma Stake
November 18, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Canterbury Park Capital has acquired around 58.2 million additional common shares of Paragon Pharmacies Ltd. (TSX: PGN), for around C$23.2 million. It now holds over 68 million shares, or a 69.9% ownership position.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
MORE ON THIS TOPIC
Insights
Programmable RNA 2.0: Beyond the First mRNA Revolution
February 5, 2026
·
1 min read
·
Jennifer Smith-Parker
Earnings
Novartis Sticks With M&A Strategy of Building Early Pipeline, Searching for Near-Launches
February 4, 2026
·
2 min read
·
Tristan Manalac
Earnings
Merck Bats Away ‘Modest Growth’ Accusations, Touts Broad Pipeline
February 3, 2026
·
2 min read
·
Dan Samorodnitsky
Deals
Roche Keeps the Deals Coming With up to $1.7B SangeneBio RNAi Pact
February 3, 2026
·
1 min read
·
Tristan Manalac
